Mission Wealth Management’s AbCellera Biologics ABCL Stock Holding History

Mission Wealth Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,651	Closed	-$36.4K	–	729
2025 Q4	$36.4K	Hold	10,651	–	–	﹤0.01%	729
2025 Q3	$53.6K	Hold	10,651	–	–	﹤0.01%	695
2025 Q2	$36.5K	Hold	10,651	–	–	﹤0.01%	678
2025 Q1	$23.8K	Hold	10,651	–	–	﹤0.01%	666
2024 Q4	$31.2K	Hold	10,651	–	–	﹤0.01%	654
2024 Q3	$27.7K	Hold	10,651	–	–	﹤0.01%	676
2024 Q2	$31.5K	Hold	10,651	–	–	﹤0.01%	659
2024 Q1	$48.3K	Hold	10,651	–	–	﹤0.01%	673
2023 Q4	$60.8K	Hold	10,651	–	–	﹤0.01%	575
2023 Q3	$49K	Hold	10,651	–	–	﹤0.01%	540
2023 Q2	$68.8K	Hold	10,651	–	–	﹤0.01%	537
2023 Q1	$80.3K	Hold	10,651	–	–	﹤0.01%	522
2022 Q4	$108K	Hold	10,651	–	–	0.01%	507
2022 Q3	$105K	Hold	10,651	–	–	0.01%	487
2022 Q2	$113K	Hold	10,651	–	–	0.01%	493
2022 Q1	$104K	Hold	10,651	–	–	﹤0.01%	521
2021 Q4	$152K	Sell	10,651 -20,000	-65%	-$304K	0.01%	523
2021 Q3	$614K	Hold	30,651	–	–	0.03%	252
2021 Q2	$674K	Buy	+30,651	New	+$845K	0.04%	233

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mission Wealth Management's ABCL Position: Q1 2026 in Review

Mission Wealth Management sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 10,651 shares — an estimated $36.4K sold.

Mission Wealth Management first reported a position in ABCL in Q2 2021 and held it in 19 quarters. The position peaked at $674K in Q2 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Mission Wealth Management reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
Mission Wealth Management sold 10,651 AbCellera Biologics shares in Q1 2026, an estimated $36.4K.
Mission Wealth Management first reported a position in AbCellera Biologics in Q2 2021 and held it in 19 quarters.
Mission Wealth Management's AbCellera Biologics position peaked at $674K in Q2 2021.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Mission Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.